Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Tumori|July 1, 1995
Alpha interferon as initial treatment of essential thrombocythemia. Analysis after two years of follow-upE M Pogliani, F Rossini, I Miccolis, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1994
Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factorsF Rossini, P Pioltelli, S Mingozzi, et al.Leukemia & Lymphoma|September 1, 1993
Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcomeR Bassan, R Battista, G Corneo, et al.Scandinavian Journal of Immunology|June 1, 1993
Expression of beta 2m-free HLA class I heavy chains in neuroblastoma cell linesA Marozzi, R Meneveri, G Bunone, et al.Pacing and Clinical Electrophysiology : PACE|April 1, 1989
Epidural spinal electrostimulatory system (ESES) in the management of diabetic foot and peripheral arteriopathiesI Franzetti, A De Nale, A Bossi, et al.Leukemia & Lymphoma|June 1, 1997
Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costsR Bassan, T Lerede, E Di Bona, et al.British Journal of Haematology|April 7, 1999
Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemiaR Bassan, T Lerede, E Di Bona, et al.Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.Journal of the National Cancer Institute|October 19, 2000
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571C Gambacorti-Passerini, R Barni, P le Coutre, et al.The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsR Bassan, E Pogliani, P Casula, et al.Pageof 9